Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply
JAMA Oncol
.
2023 Feb 1;9(2):277-278.
doi: 10.1001/jamaoncol.2022.6147.
Authors
Matthew H G Katz
1
,
Joseph M Herman
2
,
Eileen M O'Reilly
3
Affiliations
1
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
2
Northwell Cancer Institute, National Cancer Institute Community Oncology Research Program, Manhasset, New York.
3
Memorial Sloan Kettering Cancer Center, New York, New York.
PMID:
36454565
DOI:
10.1001/jamaoncol.2022.6147
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Fluorouracil / therapeutic use
Humans
Neoadjuvant Therapy*
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / radiotherapy
Substances
Fluorouracil